Missing: Pevion Biotech's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Pevion Biotech's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Pevion Biotech Patents
Pevion Biotech has filed 1 patent.
Immune system, Immunology, RNA, DNA, Vaccines
Immune system, Immunology, RNA, DNA, Vaccines
Latest Pevion Biotech News
Mar 7, 2018
Sep 7, 2010 6:10am BERNE, Switzerland, September 7, 2010 /PRNewswire/ -- Pevion Biotech AG announced today the appointment of Evert Kueppers as its new Chief Executive Officer, succeeding Thomas Stauffer. "We would like to thank Thomas for his excellent contributions over the years and wish him all the best in his new position," said Klaus Breiner of BB Biotech Ventures and Chairman of the Board of Directors. "We are very pleased that we could attract Evert to become the new CEO of Pevion. With his experience and hands-on approach, Evert is a perfect fit to lead the Company in this exciting phase." Prior to joining Pevion, Evert Kueppers was CEO of Pieris AG, a Munich-based biotechnology company, which he successfully restructured and refinanced, raising a total US$ 45 million. Before that, Evert was Head of Business Development at IDEA AG, where he was instrumental in corporate development and partnering activities. Before joining the biotech industry, he spent several years in the International Operations of BASF Pharma (now Abbott Labs) and was a management consultant with the global health care team of AT Kearney in London. Evert holds an advanced degree in Biomedical Sciences from Leiden University and an MBA from RSM/Erasmus University. He currently also serves on the Board of Cenix Bioscience. At the same time, the Company secured further financing commitments of CHF 10 million from its existing investors, BZ Bank, BB Biotech Ventures and Core Capital. Pevion plans to raise additional financing over the next twelve months to broaden and further its pipeline. "Pevion has reached an important stage in its development as its candidate products reach for critical milestones. This financing commitment should take the Company a long way towards achieving further product validation and reaching important company value inflection points," added Joseph Manko of BZ Bank and member of the Board of Directors. "We are looking forward to working with Evert to deliver on Pevion's potential." "The use of virus-like particles is a proven approach to develop effective and safe vaccines," said Evert Kueppers, CEO of Pevion Biotech. "I am excited to take on this new challenge to bring the company to the next level, working with a team of highly skilled researchers and vaccine developers." About Pevion Biotech Pevion Biotech is an independent Swiss vaccine company that develops next generation vaccines based on its clinically and commercially validated virosome technology. Its proprietary pipeline includes a clinical stage candidiasis vaccine and preclinical programmes in RSV and pandemic flu. A clinical stage malaria vaccine candidate has been outlicensed and the Company`s technology is being used for an HIV vaccine currently in human trials. The Company has in-house development capability and expertise, including a state-of-the-art and industrially scalable GMP manufacturing process. Located near Bern, Pevion was founded in 2002 as an industrial spin-off of Bachem AG (SWX: BANB) and Berna Biotech, now Crucell, (SWX: CRX), and raised a total of CHF 45 million to date from its founders and investors, BZ Bank, BB Biotech Venture and Core Capital Partners. About Virosomes Virosomes are the only regulatory and market-approved vaccine technology to fulfill carrier and adjuvant functions in one. Essentially, virosomes represent reconstituted empty influenza virus envelopes, devoid of the genetic material of the source virus. As such, virosomes do not replicate and are therefore an ideal combination of carrier plus adjuvant for almost any given antigen, including peptide or protein derived antigens. Two virosome-based vaccines (Epaxal(R) and Inflexal(R) V, marketed by Crucell) are licensed in over 40 countries, and more than 50 million doses of these vaccines have been commercially distributed, thereby providing a solid safety and efficacy track record. Contact: Evert Kueppers, CEO Phone: +41-31-550-44-44 E-Mail: [email protected] SOURCE Pevion Biotech AG
Pevion Biotech Frequently Asked Questions (FAQ)
When was Pevion Biotech founded?
Pevion Biotech was founded in 2002.
Where is Pevion Biotech's headquarters?
Pevion Biotech's headquarters is located at Bern.
What is Pevion Biotech's latest funding round?
Pevion Biotech's latest funding round is Unattributed VC.
How much did Pevion Biotech raise?
Pevion Biotech raised a total of $9.89M.
Who are the investors of Pevion Biotech?
Investors of Pevion Biotech include Core Capital Partners, BB Biotech Ventures, BZ Bank Aktiengesellschaft, Bellevue Asset Management and Bachem.
Who are Pevion Biotech's competitors?
Competitors of Pevion Biotech include Apitope, Portola Pharmaceuticals, Vitatex, ACT Biotech, Immunovaccine and 12 more.
Compare Pevion Biotech to Competitors
DCV Technologies, Inc. (DCV) is a private, biopharmaceutical company focusing on the development of therapeutic vaccines for reproductive tract and other cancers.
BioSphere was born in 1998 as the biotechnology division of S.F.I.R. S.p.A. with the aim of diversifying the activities in the biotech sector, and in particular for the development of technologies for the conversion of sugars and by-products of the agro-food industry into added value products. In 2002 BioSphere became an independent company with the capital fully hold by S.F.I.R. SpA. Today, BioSphere develops its own R&D projects and offers to other companies an efficient and qualified outsourcing service.
SiTec Consulting was established in 1996, on the basis of long experience in pharmaceutical R&D. The company developed a range of expertise working with pharmaceutical and biotech companies in the United States and in Europe.n SiTec Consulting offers pharmaceutical and biotechnology companies a variety of services in the areas of preformulation, drug development, drug delivery and formulation technologies evaluation, regulatory and cGLP/cGMP compliance. The company can actively collaborate with start-up pharmaceutical and drug delivery companies to provide scientific and strategic support in the establishment of the new company's activities. The company emphasize open communication, active involvement with the client and continuous feedback.n Networking is one of the company's assets, allowing us to cover the complex demands of the R&D process. The company have access to laboratories and equipment and resources, located at the Bioindustry Park Canavese, and at selected universities and research centers in Europe. This aims to give the possibility to conduct and manage experimental parts of projects at the company's clients' request.n The company value the importance of high quality training. In addition to the hands-on experience the company can provide to the company's clients, SiTec is an authorized representative of the Center for Professional Advancement, a worldwide private institution dedicated to the provision of continuing technical and scientific education at a professional level.
Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.
BioJENC is a biotech company developing peptide vacines against human immunodeficiency virus (HIV) and other challenging infectious agents.
Hawaii Biotech (HBI) is a privately held biotechnology company focused on the research and development of vaccines for established and emerging infectious diseases. The company has developed expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines. Lead vaccine candidates in clinical development target the West Nile virus and Dengue virus. Additional recombinant protein subunits vaccine candidates produced from this protein production platform are currently under development.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.